Published: August 13, 2022 DOI: 10.7759/cureus.27979 Cite this article as: Thandavaram A, Channar A, Purohit A, et al. (August 13, 2022) The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review. Cureus 14(8): e27979. doi:10.7759/cureus.27979 Article reads consist of online article views and PDF downloads.
In conclusion, bezlotoxumab is a great option adjunctive with standard of care CDI antibiotics for the prevention of rCDI in high-risk adults.